4D Molecular Therapeutics CLO Scott Bizily Stock Transactions and Option Exercise

This Form 4 filing reports stock transactions by Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (FDMT). On June 23, 2026, Bizily exercised stock options for 9,810 shares at $4.14 per share and immediately sold the same number of shares at $12.00 per share, resulting in a net gain. The option exercise was part of a Rule 16b-3 exempt transaction under the company's Employee Stock Purchase Plan. Following these transactions, Bizily's direct holdings decreased from 18,427 shares to 8,617 shares of common stock, while retaining 63,785 stock options. The stock options vest monthly over four years starting from March 6, 2025, and expire on March 5, 2035. These transactions represent routine executive stock option exercises and sales, indicating the officer is monetizing vested equity while maintaining significant option holdings.